Posted by admin on Jul 30th, 2022

Apollo Endosurgery (NASDAQ:APEN – Get Rating) and Paragon 28 (NYSE:FNA – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, analyst recommendations, risk, institutional ownership and dividends.

This is a summary of recent ratings and price targets for Apollo Endosurgery and Paragon 28, as reported by MarketBeat.

Apollo Endosurgery currently has a consensus target price of $12.80, indicating a potential upside of 128.16%. Paragon 28 has a consensus target price of $25.50, indicating a potential upside of 34.21%. Given Apollo Endosurgery’s higher probable upside, equities research analysts plainly believe Apollo Endosurgery is more favorable than Paragon 28.

94.6% of Apollo Endosurgery shares are owned by institutional investors. Comparatively, 12.3% of Paragon 28 shares are owned by institutional investors. 30.0% of Apollo Endosurgery shares are owned by company insiders. Comparatively, 19.5% of Paragon 28 shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

This table compares Apollo Endosurgery and Paragon 28’s net margins, return on equity and return on assets.

This table compares Apollo Endosurgery and Paragon 28’s top-line revenue, earnings per share and valuation.

Paragon 28 has higher revenue and earnings than Apollo Endosurgery.

Paragon 28 beats Apollo Endosurgery on 7 of the 10 factors compared between the two stocks.

Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices. The company offers OverStitch and OverStitch Sx Endoscopic Suturing Systems that enable advanced endoscopic procedures by allowing physicians to sutures and secure the approximation of tissue through a flexible endoscope. It also provides Orbera, an intragastric balloon system that reduces stomach capacity causing patients to consume less following the procedure, as well as delays gastric content emptying under the Orbera Intragastric Balloon System, BIB, and Orbera365 Managed Weight Loss System brands. Additionally, the company offers X-Tack Endoscopic HeliX Tacking System, a suture-based device for closing and healing defects in the lower and upper gastrointestinal tract. The company sells its products to medical services providers; and hospitals, outpatient surgical centers, clinics, and physicians in the United States, Australia, Costa Rica, and other European countries. Apollo Endosurgery, Inc. was founded in 2005 and is headquartered in Austin, Texas.

Paragon 28, Inc. designs, develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems. The company also provides precision guide technology for various procedures consisting of fusion, a procedure to address bunion deformities that fuses two bones on the big toe; first tarsometatarsal arthrodesis; and metatarsal osteotomy for bunion correction, medial column beaming for charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis. In addition, it offers monster, mini monster, and joust beaming screw systems for use in bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, fracture repair, and fracture fixation; and APEX 3D total ankle replacement systems; total talus spacers to replace the talus and bone in the ankle that connects the leg and foot. Further, the company provides bunion or hallux valgus correction systems, including nail systems phantom intramedullary nail systems for the treatment of severe hallux valgus; and various orthobiologics comprising bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix, as well as PRESERVE bone graft systems for homologous application. Additionally, it offers soft tissue fixation systems, titanium sprayed polyetheretherketone implants, nitinol staple systems, stabilization systems, and curved instruments. The company serves hospitals and ambulatory surgery centers through a network of sales representatives and stocking distributors. Paragon 28, Inc. was founded in 2010 and is headquartered in Englewood, Colorado.

Receive News & Ratings for Apollo Endosurgery Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Endosurgery and related companies with MarketBeat.com's FREE daily email newsletter.

Verizon Communications Inc. (NYSE:VZ) Given Consensus Rating of “Hold” by Analysts

BMO Capital Markets Increases Precision Drilling (TSE:PD) Price Target to C$140.00